Merck & Co’s (NYSE: MRK) checkpoint blocker and commercial super-blockbuster Keytruda (pembrolizumab) has scored another Phase III success, in triple-negative breast cancer (TNBC).
Results from the KEYNOTE-522 trial show the benefits of combining the immunotherapy with chemotherapy as a pre-operative treatment and then continuing as a single agent after surgery.
The study met its dual primary endpoint of event-free survival (EFS) for the treatment of patients with high-risk early-stage TNBC, according to an interim analysis conducted by data monitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze